Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.64 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1677932 | 0.98 | EPHX2 (0.62) | EPHX2P2RX7MEN1KMT2ATDP1 | |
| SCHEMBL23023053 | 0.90 | EPHX2 (0.53) | EPHX2P2RX7MEN1KMT2ATDP1 | |
| SCHEMBL4715003 | 0.83 | GRIN2D (0.48) | EPHX2P2RX7MEN1KMT2ATDP1 | |
| SCHEMBL10067533 | 0.83 | P2RX7 (0.67) | EPHX2P2RX7MEN1KMT2AALDH1A1 | |
| SCHEMBL19173632 | 0.80 | CHRM2 (0.53) | EPHX2P2RX7MEN1KMT2ACHRM2 | |
| SCHEMBL4717867 | 0.78 | OPRM1 (0.47) | EPHX2MEN1KMT2AALDH1A1 | |
| SCHEMBL3241417 | 0.77 | EPHX2 (0.60) | EPHX2P2RX7MEN1KMT2AMAOA | |
| SCHEMBL1677723 | 0.76 | EPHX2 (0.53) | EPHX2P2RX7MEN1KMT2ACHRM2 | |
| SCHEMBL23323137 | 0.76 | P2RX7 (0.53) | EPHX2P2RX7MEN1KMT2ACHRM2 | |
| SCHEMBL4716912 | 0.75 | SPHK2 (0.52) | EPHX2P2RX7MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-02-25 | — | — | US | disclosed |
| EP-1904439-A2 | SPHINGOSINE KINASE INHIBITORS | Apogee Biothechnology Corporation (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006138660-A2 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | EPHX2 3395/4885P2RX7 3794/4885MEN1 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.